CARE Ratings upgrades CORONA Remedies to CARE A+
CORONA Remedies (CORONA) said CARE Ratings has upgraded its credit rating to CARE A+. The company is valued at about ₹12,558 crore.
What happened
In a filing with the BSE on 30 September 2026 at 07:16 PM, CORONA Remedies (CORONA) said that CARE Ratings has upgraded its credit rating to CARE A+.
From the filing: "Stable / CARE A1 Copy of the credit rating letter issued by CARE is enclosed herewith."
Company snapshot
CORONA Remedies is a small-cap company in the Healthcare sector, with a market value of about ₹12,558 crore.
The stock last traded at ₹2,053.3, against a 52-week range of ₹1,336.6–₹2,292.4 (10.4% below the high).
Before this filing the shares had moved −1.3% over the month and +5.0% over three months. Average daily turnover over the last 20 sessions was about ₹12.23 crore.
Promoters held 69.00% at the end of Q1 FY27. Foreign institutions owned 3.63% and domestic institutions 12.90%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 361 | 52.3 | 8.55 |
| Q3 FY26 | 342 | 41.3 | 6.75 |
| Q4 FY26 | 353 | 45.3 | 7.41 |
| Q1 FY27 | 422 | 60.1 | 9.83 |
What history shows
BCEIE has no earlier credit rating filing from this company on record since May 2026.
Across 26 similar disclosures by other Healthcare companies, shares moved −0.0% on average the next day and +2.0% over five days; 58% of them rose the next day.
Market-wide, 1,190 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.